Tenax Therapeutics, Inc. (TENX)
1.62
+0.01
(+0.62%)
USD |
NASDAQ |
Nov 13, 16:00
1.62
0.00 (0.00%)
After-Hours: 19:59
Tenax Therapeutics Enterprise Value : -39.96M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | -39.96M |
| November 12, 2026 | -40.42M |
| November 11, 2026 | -36.77M |
| November 10, 2026 | -36.77M |
| November 09, 2026 | -32.67M |
| November 06, 2026 | -36.77M |
| November 05, 2026 | -39.50M |
| November 04, 2026 | -31.31M |
| November 03, 2026 | -29.94M |
| November 02, 2026 | -31.76M |
| October 30, 2026 | -32.22M |
| October 29, 2026 | -29.03M |
| October 28, 2026 | -28.12M |
| October 27, 2026 | -35.41M |
| October 26, 2026 | -39.05M |
| October 23, 2026 | -35.41M |
| October 22, 2026 | -33.58M |
| October 21, 2026 | -39.50M |
| October 20, 2026 | -39.50M |
| October 19, 2026 | -44.51M |
| October 16, 2026 | -51.80M |
| October 15, 2026 | -44.97M |
| October 14, 2026 | -43.83M |
| October 13, 2026 | -40.87M |
| October 12, 2026 | -30.40M |
| Date | Value |
|---|---|
| October 09, 2026 | -28.58M |
| October 08, 2026 | -29.03M |
| October 07, 2026 | -26.75M |
| October 06, 2026 | -25.84M |
| October 05, 2026 | -24.48M |
| October 02, 2026 | -23.57M |
| October 01, 2026 | -25.84M |
| September 30, 2026 | -27.67M |
| September 29, 2026 | -59.19M |
| September 28, 2026 | -58.87M |
| September 25, 2026 | -60.15M |
| September 24, 2026 | -57.59M |
| September 23, 2026 | -57.27M |
| September 22, 2026 | -55.99M |
| September 21, 2026 | -57.91M |
| September 18, 2026 | -57.27M |
| September 17, 2026 | -58.55M |
| September 16, 2026 | -59.83M |
| September 15, 2026 | -59.51M |
| September 14, 2026 | -58.55M |
| September 11, 2026 | -58.55M |
| September 10, 2026 | -55.67M |
| September 09, 2026 | -49.92M |
| September 08, 2026 | -54.72M |
| September 04, 2026 | -55.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exicure, Inc. | 5.167M |
| Century Therapeutics, Inc. | 219.34M |
| Absci Corp. | 1.286B |
| Celularity, Inc. | 87.70M |
| Cardio Diagnostics Holdings, Inc. | 1.890M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.70M |
| Total Expenses (Quarterly) | 16.70M |
| EPS Diluted (Quarterly) | -0.3125 |
| Earnings Yield | -85.79% |
| Normalized Earnings Yield | -85.79 |